CSPHF (CStone Pharmaceuticals) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSPHF CStone Pharmaceuticals CSPHF
42 GF Score
Price $0.70
GF Value $0.18
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals 3-Month Share Buyback Ratio?

CStone Pharmaceuticals CSPHF 42 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates CSPHF with a GF Score™ of 42/100 and a GF Value™ of $0.18 (Significantly Overvalued). The stock has 7 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

CSPHF
42GF Score
CStone Pharmaceuticals CSPHF
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
CStone Pharmaceuticals (CSPHF) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for CStone Pharmaceuticals and its competitors.
Is CStone Pharmaceuticals' 3-Month Share Buyback Ratio too high?
CStone Pharmaceuticals' current 3-Month Share Buyback Ratio is 0.00. Overall, CStone Pharmaceuticals has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' 3-Month Share Buyback Ratio compare to VRTX and REGN?
CStone Pharmaceuticals' 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for CStone Pharmaceuticals and its competitors. CStone Pharmaceuticals's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (CSPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.18, compared to a current price of $0.70 — trading 288.9% above its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. CStone Pharmaceuticals' overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For CStone Pharmaceuticals (CSPHF), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CStone Pharmaceuticals (CSPHF) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of $0.70 is trading 288.9% above its estimated GF Value™ of $0.18. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CSPHF:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: $0.18 vs. price of $0.70 (288.9% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the CSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Other Exchanges 02616:Hong KongPH4:Germany
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
42GF Score

Get the complete analysis for CSPHF

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$0.18
GF Value